ADGRE5

Across TCGA pan-cancer cohorts, ADGRE5 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of ADGRE5’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ADGRE5 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ADGRE5 is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.

KIRC, HNSC, and LUAD are the cancer types where ADGRE5 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ADGRE5 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+1.467	<.001	11	view →
HNSC	All	III,IV	+1.048	<.001	10	view →
LUAD	Male	All	−1.567	<.001	9	view →
KIRP	All	III,IV	+1.195	<.001	9	view →
THCA	All	II,III,IV	+0.630	<.001	9	view →
LUSC	Female	II,III,IV	−2.445	<.001	8	view →
KICH	Female	All	−1.999	<.001	8	view →
COAD	Female	All	+0.568	<.001	8	view →
STAD	Male	II,III,IV	+1.873	<.001	7	view →
BLCA	All	All	−1.098	<.001	7	view →
UCEC	All	All	−1.953	<.001	6	view →
BRCA	All	III,IV	−0.736	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

ADGRE5–KIRC

Open the KIRC breakdown →